Re: getting her2+ER- bc to reexpress ER & consequences more complicated than thought
Laurel,
Not sure this manipulation of Her2+/Er- proves that naturally ER+/Her2+ cancers never respond to estrogen inhibition.
But..it does seem to be vague on clinical implications.
From what I've read, Fulvestrant may be the top "E-hibitor" for Her2+. But I think Femara is thought to reduce estrogen the most in terms of aromatase inhibitors. Fulvestrant seems to have the best chance of working after other e-hibitors are spent so it might make sense to use Femara first. Alternating low dose e to resensitize might extend use of all the e-hibitors.
|